Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) — MITO 26  

Carcinosarcoma, Ovarian Clinical Trial

Official title: Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)

Status Completed

Clinical Trial Summary

Multicenter phase II study on trabectedin in patients advanced uterine and ovarian carcinosarcoma. Patients will receive trabectedin until disease progression or unacceptable toxicity. Disease response evaluation will be assessed every 9 weeks.

Clinical Trial Description

This is a Phase II, multi-centre, single arm study aiming at evaluating efficacy and toxicity of Trabectedin in a population of advanced or recurrent ovarian and uterine carcinosarcoma.

Trabectedin will be infused at the dose of 1.3 mg/m2 as a 3- hour iv infusion every 3 weeks via a central venous catheter. ;

Related Conditions & MeSH terms

• Carcinosarcoma
• Carcinosarcoma, Ovarian
• Carcinosarcomas Uterine
• Mixed Tumor, Mullerian

• NCT number: NCT02993705
• Study type: Interventional
• Source: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• Status: Completed
• Phase: Phase 2
• Start date: February 22, 2017
• Completion date: November 13, 2019